Effects of melatonin on physical fatigue and other symptoms in patients with advanced cancer receiving palliative care: A double-blind placebo-controlled crossover trial

Cancer

Volumn 121, Issue 20, 2015, Pages 3727-3736

  Lund Rasmussen, Charlotte ^a   Klee Olsen, Marc ^a   Thit Johnsen, Anna ^a   Aagaard Petersen, Morten ^a   Lindholm, Helena ^a   Andersen, Line ^a   Villadsen, Birgit ^a   Groenvold, Mogens ^a,b   Pedersen, Lise ^a  

^a BISPEBJERG HOSPITAL   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

fatigue; hospice and palliative care nursing; melatonin; neoplasms; palliative care; quality of health care; quality of life

Indexed keywords

MELATONIN; PLACEBO;

ADULT; ADVANCED CANCER; ARTICLE; CANCER PALLIATIVE THERAPY; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DYSTHYMIA; EMOTION; EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER QUALITY OF LIFE QUESTIONNAIRE; EVENING DOSAGE; FATIGUE; FEMALE; FUNCTIONAL STATUS ASSESSMENT; HUMAN; INSOMNIA; LOSS OF APPETITE; MAJOR CLINICAL STUDY; MALE; MULTIDIMENSIONAL FATIGUE INVENTORY; OPEN STUDY; PAIN; PRIORITY JOURNAL; QUALITY OF LIFE; QUALITY OF LIFE ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; SYMPTOM; TRIPLE BLIND PROCEDURE; AGED; COMPLICATION; DRUG ADMINISTRATION; MIDDLE AGED; NEOPLASMS; ORAL DRUG ADMINISTRATION; PALLIATIVE THERAPY; PATHOLOGY; PATIENT COMPLIANCE; VERY ELDERLY;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FATIGUE; FEMALE; HUMANS; MALE; MELATONIN; MIDDLE AGED; NEOPLASMS; PALLIATIVE CARE; PATIENT COMPLIANCE; QUALITY OF LIFE;

EID: 84943526948     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.29563     Document Type: Article

References (47)

1. Stromgren AS, Goldschmidt D, Groenvold M, et al., Self-assessment in cancer patients referred to palliative care: a study of feasibility and symptom epidemiology. Cancer. 2002; 94: 512-520.
2. Fernandes R, Stone P, Andrews P, Morgan R, Sharma S,. Comparison between fatigue, sleep disturbance, and circadian rhythm in cancer inpatients and healthy volunteers: evaluation of diagnostic criteria for cancer-related fatigue. J Pain Symptom Manage. 2006; 32: 245-254.
3. Lundh Hagelin C, Seiger A, Furst CJ,. Quality of life in terminal care-with special reference to age, gender and marital status. Support Care Cancer. 2006; 14: 320-328.
4. Walsh D, Donnelly S, Rybicki L,. The symptoms of advanced cancer: relationship to age, gender, and performance status in 1,000 patients. Support Care Cancer. 2000; 8: 175-179.
5. Littlewood TJ, Kallich JD, San Miguel J, Hendricks L, Hedenus M,. Efficacy of darbepoetin alfa in alleviating fatigue and the effect of fatigue on quality of life in anemic patients with lymphoproliferative malignancies. J Pain Symptom Manage. 2006; 31: 317-325.
6. Morita T, Tsunoda J, Inoue S, Chihara S,. Contributing factors to physical symptoms in terminally-ill cancer patients. J Pain Symptom Manage. 1999; 18: 338-346.
7. DeMuro RL, Nafziger AN, Blask DE, Menhinick AM, Bertino JS Jr,. The absolute bioavailability of oral melatonin. J Clin Pharmacol. 2000; 40: 781-784.
8. Dollins AB, Zhdanova IV, Wurtman RJ, Lynch HJ, Deng MH,. Effect of inducing nocturnal serum melatonin concentrations in daytime on sleep, mood, body temperature, and performance. Proc Natl Acad Sci USA. 1994; 91: 1824-1828.
9. Spiegel D,. Losing sleep over cancer. J Clin Oncol. 2008; 26: 2431-2432.
10. Mormont MC, Waterhouse J, Bleuzen P, et al., Marked 24-h rest/activity rhythms are associated with better quality of life, better response, and longer survival in patients with metastatic colorectal cancer and good performance status. Clin Cancer Res. 2000; 6: 3038-3045.
11. Brzezinski A,. Melatonin in humans. N Engl J Med. 1997; 336: 186-195.
12. Bartsch C, Bartsch H, Schmidt A, Ilg S, Bichler KH, Fluchter SH,. Melatonin and 6-sulfatoxymelatonin circadian rhythms in serum and urine of primary prostate cancer patients: evidence for reduced pineal activity and relevance of urinary determinations. Clin Chim Acta. 1992; 209: 153-167.
13. Jung B, Ahmad N,. Melatonin in cancer management: progress and promise. Cancer Res. 2006; 66: 9789-9793.
14. Blask DE, Dauchy RT, Sauer LA,. Putting cancer to sleep at night: the neuroendocrine/circadian melatonin signal. Endocrine. 2005; 27: 179-188.
15. Altun A, Ugur-Altun B,. Melatonin: therapeutic and clinical utilization. Int J Clin Pract. 2007; 61: 835-845.
16. Hoang BX, Shaw DG, Pham PT, Levine SA,. Neurobiological effects of melatonin as related to cancer. Eur J Cancer Prev. 2007; 16: 511-516.
17. Ravindra T, Lakshmi NK, Ahuja YR,. Melatonin in pathogenesis and therapy of cancer. Indian J Med Sci. 2006; 60: 523-535.
18. Malhotra S, Sawhney G, Pandhi P,. The therapeutic potential of melatonin: a review of the science. MedGenMed. 2004; 6: 46.
19. Lissoni P,. Is there a role for melatonin in supportive care? Support Care Cancer. 2002; 10: 110-116.
20. Lissoni P, Barni S, Mandala M, et al., Decreased toxicity and increased efficacy of cancer chemotherapy using the pineal hormone melatonin in metastatic solid tumour patients with poor clinical status. Eur J Cancer. 1999; 35: 1688-1692.
21. Lissoni P, Barni S, Fossati V, et al., A randomized study of neuroimmunotherapy with low-dose subcutaneous interleukin-2 plus melatonin compared to supportive care alone in patients with untreatable metastatic solid tumour. Support Care Cancer. 1995; 3: 194-197.
22. Lissoni P, Mandala M, Brivio F,. Abrogation of the negative influence of opioids on IL-2 immunotherapy of renal cell cancer by melatonin. Eur Urol. 2000; 38: 115-118.
23. Lissoni P, Tancini G, Barni S, et al., Treatment of cancer chemotherapy-induced toxicity with the pineal hormone melatonin. Support Care Cancer. 1997; 5: 126-129.
24. Lissoni P, Barni S, Rovelli F, et al., Neuroimmunotherapy of advanced solid neoplasms with single evening subcutaneous injection of low-dose interleukin-2 and melatonin: preliminary results. Eur J Cancer. 1993; 29A: 185-189.
25. Lissoni P, Paolorossi F, Ardizzoia A, et al., A randomized study of chemotherapy with cisplatin plus etoposide versus chemoendocrine therapy with cisplatin, etoposide and the pineal hormone melatonin as a first-line treatment of advanced non-small cell lung cancer patients in a poor clinical state. J Pineal Res. 1997; 23: 15-19.
26. Lissoni P, Viviani S, Bajetta E, et al., A clinical study of the pineal gland activity in oncologic patients. Cancer. 1986; 57: 837-842.
27. Groenvold M, Petersen MA, Aaronson NK, et al,; EORTC Quality of Life Group. The development of the EORTC QLQ-C15-PAL: a shortened questionnaire for cancer patients in palliative care. Eur J Cancer. 2006; 42: 55-64.
28. Edge S, Byrd DR, Compton CC, et al., (editors) AJCC Cancer Staging Manual 7th Edition, London: New York, NY: Springer.
29. Koller M, Aaronson NK, Blazeby J, et al,; EORTC Quality of Life Group. Translation procedures for standardised quality of life questionnaires: the European Organisation for Research and Treatment of Cancer (EORTC) approach. Eur J Cancer. 2007; 43: 1810-1820.
30. Smets EMA, Garssen B, Bonke B, De Haes JC,. The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue. J Psychosom Res. 1995; 39: 315-325.
31. King MT,. The interpretation of scores from the EORTC quality of life questionnaire QLQ-C30. Qual Life Res. 1996; 5: 555-567.
32. SAS Institute Inc. SAS/STAT 9.1 User's Guide. Cary, NC: SAS Institute Inc; 2004.
33. Pocock SJ,. Clinical Trials: A Practical Approach, Crossover Trials, Chichester, UK: John Wiley & Sons Ltd, 1996: 110-122.
34. Yuan Y,. Multiple imputation using SAS software. J Stat Softw. 2011; 45: 1-25.
35. Stromgren AS, Sjogren P, Goldschmidt D, Petersen MA, Pedersen L, Groenvold M,. Symptom priority and course of symptomatology in specialized palliative care. J Pain Symptom Manage. 2006; 31: 199-206.
36. Lin JM, Brimmer DJ, Maloney EM, Nyarko E, Belue R, Reeves WC,. Further validation of the Multidimensional Fatigue Inventory in a US adult population sample. Popul Health Metr. 2009; 7: 18.
37. Hedlund L, Gyllensten AL, Hansson L,. A psychometric study of the Multidimensional Fatigue Inventory to assess fatigue in patients with schizophrenia spectrum disorders. Community Ment Health J. 2015; 51: 377-382.
38. Meek PM, Nail LM, Barsevick A, et al., Psychometric testing of fatigue instruments for use with cancer patients. Nurs Res. 2000; 49: 181-190.
39. Dehais C, Souvannavong V, Nguyen BK, et al., An evaluation of fatigue in patients with glioblastoma relapse treated with the combination of irinotecan-bevacizumab [in French]. Rev Neurol (Paris). 2011; 167: 841-846.
40. Eichler C, Pia M, Sibylle M, Sauerwald A, Friedrich W, Warm M,. Cognitive behavioral therapy in breast cancer patients-a feasibility study of an 8 week intervention for tumor associated fatigue treatment. Asian Pac J Cancer Prev. 2015; 6: 1063-1067.
41. Riesenberg H, Lubbe AS,. In-patient rehabilitation of lung cancer patients-a prospective study. Support Care Cancer. 2009; 18: 877-882.
42. Mills EJ, Chan AW, Wu P, Vail A, Guyatt GH, Altman DG,. Design, analysis, and presentation of crossover trials. Trials. 2009; 10: 27.
43. Bellon A,. Searching for new options for treating insomnia: are melatonin and ramelteon beneficial? J Psychiatr Pract. 2006; 12: 229-243.
44. Deacon S, Arendt J,. Melatonin-induced temperature suppression and its acute phase-shifting effects correlate in a dose-dependent manner in humans. Brain Res. 1995; 688: 77-85.
45. Andrade C, Srihari BS, Reddy KP, Chandramma L,. Melatonin in medically ill patients with insomnia: a double-blind, placebo-controlled study. J Clin Psychiatry. 2001; 62: 41-45.
46. Seely D, Wu P, Fritz H, et al., Melatonin as adjuvant cancer care with and without chemotherapy: a systematic review and meta-analysis of randomized trials. Integr Cancer Ther. 2012; 11: 293-303.
47. Del Fabbro E, Dev R, Hui D, Palmer L, Bruera E,. Effects of melatonin on appetite and other symptoms in patients with advanced cancer and cachexia: a double-blind placebo-controlled trial. J Clin Oncol. 2013; 31: 1271-1276.